Loading...

Pacific Blue™ anti-human CD45 Antibody

Pricing & Availability
Clone
HI30 (See other available formats)
Regulatory Status
RUO
Workshop
IV N816
Other Names
LCA, T200
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HI30_Blue_021508
Human peripheral blood lymphocytes stained with HI30 Pacific Blue™
  • HI30_Blue_021508
    Human peripheral blood lymphocytes stained with HI30 Pacific Blue™
Compare all formats See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
304021 25 µg 100€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304029 100 tests 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304022 100 µg 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis.
For test size, the suggested use of this reagent for immunofluorescent staining is 5 µl per 106 cells in 100 µl volume.
For µg sizes, the suggested use of this reagent for immunofluorescent staining is ≤0.5 µg per 106 cells in 100 µl volume.
It is recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections9, inhibition of CD45 functions4, immunofluorescence11, Western blotting3, and spatial biology (IBEX)16,17.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Kishihara K, et al. 1993. Cell 74:143.
  3. Esser M, et al. 2001. J. Virol. 75:6173. (WB)
  4. Yamada T, et al. 2002. J. Biol. Chem. 277:28830.
  5. Nagano M, et al. 2007. Blood 110:151.
  6. Jiang Q, et al. 2008. Blood 112:2858. PubMed
  7. Morozov A, et al. 2010. Clin Cancer Res. 16:5630. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  10. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
  11. Rees LE, et al. 2003. Clin. Exp. Immunol. 134:497. (IF)
  12. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
  13. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
  14. Marquardt N, et al. 2015. J Immunol. 6:2467. PubMed
  15. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110. (IF) PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Logan PC, et al. 2018. Reprod Sci. 25:140. PubMed
  2. Rizzo MD, et al. 2019. J Pharmacol Exp Ther. 371:191. PubMed
  3. Carre C, et al. 2021. iScience. 24:102970. PubMed
  4. Sefik E, et al. 2022. Nature. 606:585. PubMed
  5. Omer-Javed A, et al. 2022. Cell. 185:2248. PubMed
  6. Shishkova D, et al. 2022. Int J Mol Sci. 23: . PubMed
  7. Li K, et al. 2023. Leukemia. 37:308. PubMed
  8. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  9. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  10. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  11. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  12. Castañeda-Partida L, et al. 2022. Discov Oncol. 13:28. PubMed
  13. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  14. Svec J, et al. 2022. Cancers (Basel). 14:. PubMed
  15. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
  16. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  17. Pan X, et al. 2022. Cell Mol Biol (Noisy-le-grand). 68:77. PubMed
  18. Kameishi S, et al. 2023. Sci Rep. 13:4421. PubMed
  19. Pelletier J, et al. 2023. iScience. 26:106385. PubMed
  20. Saez-Ayala M, et al. 2023. Nat Commun. 14:3079. PubMed
  21. Hoover MY, et al. 2023. Nat Protoc. . PubMed
  22. Chagraoui J, et al. 2021. Cell Stem Cell. 28(1):48-62.e6. PubMed
  23. Borrelli MR, et al. 2020. Stem Cells Transl Med. 1.339583333. PubMed
  24. Skowron K, et al. 2016. Sci Rep. 6:35854. PubMed
  25. Goodnough LH, et al. 2020. JBMR Plus. 4:e10398. PubMed
  26. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  27. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  28. Griffiths K, et al. 2016. J Biol Chem. 291: 12641 - 12657. PubMed
  29. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
  30. Tyurin-Kuzmin PA, et al. 2018. Sci Data. 5:180196. PubMed
  31. Pham K, et al. 2016. Am J Pathol. 186: 1537-1546. PubMed
  32. Tcymbarevich IV, et al. 2019. BMC Gastroenterol. 19:2. PubMed
  33. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  34. Rademacher MJ, et al. 2021. Sci Rep. 11:8321. PubMed
  35. Stoeckle C, et al. 2013. J Vis Exp. 79: 50951. PubMed
  36. Marsden MD, et al. 2020. Cell Rep Med. 1:100162. PubMed
  37. Chen Z, et al. 2020. Int J Biol Sci. 2.197916667. PubMed
  38. Narasimhan PB, et al. 2018. PLoS Negl Trop Dis. 12:e0006404. PubMed
  39. Queckborner S, et al. 2020. Stem Cell Res Ther. 11:15. PubMed
  40. Ângela Crespo, Jack Strominger, Tamara Tilburgs 2016. Proc Natl Acad Sci U S A. 113(52):15072-15077. PubMed
  41. Hofner T, et al. 2014. Urol Oncol. 32:678. PubMed
  42. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  43. Du X, et al. 2018. Cell Res. 28:416. PubMed
  44. Moison C, et al. 2022. Blood Adv. 6:4793. PubMed
  45. Iannetta M, et al. 2016. PLoS One. 11: 0160277. PubMed
  46. Iwabuchi R, et al. 2021. Frontiers in Immunology. 12:643040. PubMed
  47. Baccelli I, et al. 2020. Cancer Cell. 36(1):84-99. PubMed
  48. Twigger AJ, et al. 2022. Nat Commun. 13:562. PubMed
  49. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  50. Chou S, et al. 2012. Proc Natl Acad Sci U S A. 109:17573. PubMed
  51. Bohnert KL, et al. 2020. Foot Ankle Int. 41:536. PubMed
  52. Gleason M, et al. 2014. Blood. 123:3016. PubMed
  53. Cheah M, et al. 2015. Proc Natl Acad Sci U S A. 112:4725. PubMed
  54. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  55. Zee BM, et al. 2021. iScience. 24(6):102651. PubMed
  56. Kenswil KJG, et al. 2021. Cell Stem Cell. 28(4):653-670.e11. PubMed
  57. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
  58. Ambrosi TH, et al. 2020. Aging Cell. 19:e13164. PubMed
  59. Zah E, et al. 2020. Nat Commun. 11:2283. PubMed
  60. Valle A, et al. 2015. J Immunol. 194:2117. PubMed
  61. Borrelli MR, et al. 2020. Aesthet Surg J. 369:40. PubMed
  62. Zimmerman KA, et al. 2019. J Am Soc Nephrol. 30:767. PubMed
  63. Pache L, et al. 2020. Cell Rep Med. 1:100037. PubMed
  64. Sefik E, et al. 2021. Nat Biotechnol. . PubMed
  65. Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed
  66. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  67. Legrand F, et al. 2019. J Allergy Clin Immunol. 143:2227. PubMed
  68. Schiroli G et al. 2019. Cell stem cell. 24(4):551-565 . PubMed
  69. Santoni de Sio FR, et al. 2018. J Allergy Clin Immunol. 142:1909. PubMed
  70. Morozov A, et al. 2010. Clin Cancer Res. 4.576388889. PubMed
  71. Carter BZ, et al. 2019. Cancer Res. 79:1165. PubMed
  72. Li J, et al. 2017. Toxicology. 378:17. PubMed
  73. Beringer A, et al. 2019. Sci Rep. 9:8378. PubMed
  74. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  75. Rizzo MD, et al. 2019. J Neuroimmunol. 333:576969. PubMed
  76. Lu Y, et al. 2020. STAR Protoc. 1:100040. PubMed
  77. Gussarow D, et al. 2021. Front Med (Lausanne). 8:770381. PubMed
  78. Phansalkar R, et al. 2021. Elife. 10:. PubMed
  79. He L, et al. 2022. EMBO Mol Med. 14:e14990. PubMed
  80. Deleon NMD, et al. 2021. J Tissue Eng Regen Med. 15:1105. PubMed
  81. Ferrari S, et al. 2021. Nature Protocols. 16(6):2991-3025. PubMed
  82. Krampitz G, et al. 2016. Proc Natl Acad Sci U S A. 113: 4464-4469. PubMed
  83. Frangieh CJ, et al. 2021. Nat Genet. 53:332. PubMed
  84. Gopalakrishnapillai A, et al. 2021. Cancers (Basel). 13:. PubMed
  85. Borrelli MR, et al. 2020. Stem Cells Transl Med. 1.347916667. PubMed
  86. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  87. Okumura T, et al. 2019. Stem Cell Res Ther. 10:185. PubMed
  88. Li S, et al. 2020. Commun Biol. 3:26. PubMed
  89. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  90. Morgan MA, et al. 2021. Viruses. 13:. PubMed
RRID
AB_2174123 (BioLegend Cat. No. 304021)
AB_2174123 (BioLegend Cat. No. 304029)
AB_2174123 (BioLegend Cat. No. 304022)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane protein, 180-240 kD (multiple isoforms)
Distribution

Hematopoietic cells, not expressed in circulating erythrocytes or platelets

Function
TCR and BCR mediated activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
Hematopoietic stem and progenitors, Mesenchymal Stem Cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References
  1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
  2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.
Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD45 HI30 FC
Biotin anti-human CD45 HI30 FC
FITC anti-human CD45 HI30 FC
PE anti-human CD45 HI30 FC
PE/Cyanine5 anti-human CD45 HI30 FC
Purified anti-human CD45 HI30 FC,CyTOF®,IHC-P,WB,IHC-F,ICC
APC/Cyanine7 anti-human CD45 HI30 FC
PE/Cyanine7 anti-human CD45 HI30 FC
Alexa Fluor® 488 anti-human CD45 HI30 FC
Alexa Fluor® 647 anti-human CD45 HI30 FC
Pacific Blue™ anti-human CD45 HI30 FC
Alexa Fluor® 700 anti-human CD45 HI30 FC
PerCP anti-human CD45 HI30 FC
PerCP/Cyanine5.5 anti-human CD45 HI30 FC,SB
Brilliant Violet 421™ anti-human CD45 HI30 FC
Brilliant Violet 570™ anti-human CD45 HI30 FC
Brilliant Violet 510™ anti-human CD45 HI30 FC
Brilliant Violet 605™ anti-human CD45 HI30 FC
Brilliant Violet 650™ anti-human CD45 HI30 FC
Purified anti-human CD45 (Maxpar® Ready) HI30 FC,CyTOF®
Brilliant Violet 785™ anti-human CD45 HI30 FC
Brilliant Violet 711™ anti-human CD45 HI30 FC
PE/Dazzle™ 594 anti-human CD45 HI30 FC
Alexa Fluor® 594 anti-human CD45 HI30 IHC-P,SB
APC/Fire™ 750 anti-human CD45 HI30 FC
Pacific Blue™ anti-human CD45 HI30 FC
APC anti-human CD45 HI30 FC
PE/Cyanine7 anti-human CD45 HI30 FC
PE/Dazzle™ 594 anti-human CD45 HI30 FC
TotalSeq™-A0391 anti-human CD45 HI30 PG
TotalSeq™-B0391 anti-human CD45 HI30 PG
TotalSeq™-C0391 anti-human CD45 HI30 PG
PerCP/Cyanine5.5 anti-human CD45 HI30 FC
APC/Fire™ 750 anti-human CD45 HI30 FC
PE/Fire™ 640 anti-human CD45 HI30 FC
APC/Fire™ 810 anti-human CD45 HI30 FC
Spark YG™ 570 anti-human CD45 HI30 IHC-P
PE/Fire™ 700 anti-human CD45 HI30 FC
FITC anti-human CD45 HI30 FC
PerCP anti-human CD45 HI30 FC
Alexa Fluor® 660 anti-human CD45 Antibody HI30 FC
Spark Violet™ 538 anti-human CD45 HI30 FC
Spark YG™ 593 anti-human CD45 HI30 FC
GMP APC/Fire™ 750 anti-human CD45 HI30 FC
Spark Violet™ 538 anti-human CD45 HI30 FC
GMP APC anti-human CD45 HI30 FC
Spark UV™ 387 anti-human CD45 HI30 FC
GMP Pacific Blue™ anti-human CD45 HI30 FC
GMP PerCP anti-human CD45 HI30 FC
GMP FITC anti-human CD45 HI30 FC
PE anti-human CD45 HI30 FC
GMP PE/Dazzle™ 594 anti-human CD45 HI30 FC
GMP PerCP/Cyanine5.5 anti-human CD45 HI30 FC
Spark Blue™ 515 anti-human CD45 HI30 FC
TotalSeq™-D0391 anti-human CD45 HI30 PG
GMP PE/Cyanine7 anti-human CD45 HI30 FC
Spark Violet™ 500 anti-human CD45 HI30 FC
GMP PE anti-human CD45 HI30 FC
PE/Fire™ 810 anti-human CD45 HI30 FC
Spark PLUS UV395™ anti-human CD45 HI30 FC
Spark NIR™ 685 anti-human CD45 HI30 FC
Spark Violet™ 423 anti-human CD45 HI30 FC

Customers Also Purchased

APC anti-human CD3
Clone: UCHT1

FITC anti-human CD45
Clone: HI30

PE anti-human CD45
Clone: HI30

FITC anti-human CD3
Clone: UCHT1

Go To Top Version: 2    Revision Date: 04.25.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account